CB Company

Where there's a will, there's no way? According to the German legislature, the will exists to re-regulate legal industries around the hemp plant in a new and solution-oriented manner. Only seemingly are the possibilities lacking. The step backwards after the initial framework paper in the consumer goods market, the absurd BtM sword of Damocles for all industrial hemp actors, the uncertain future for medical cannabis flowers. How industry and legislators finally leave the status quo behind will be discussed in this panel discussion. Langugage: German SpeakersMoritz Förster (Moderator), www.krautinvest.de, Editor-in-ChiefDirk Heidenblut (Speaker), The German Bundestag, SPD MemberDaniel Kruse (Speaker), EIHA, PresidentDirk Heitepriem (Speaker), Branchenverband Cannabiswirtschaft, VizepräsidentDr. Ferdinand Weis (Speaker), Anwalts- und Notarkanzlei Dr. Engelhard, Weimar & Kollegen, LawyerKatanja Kurth-Grieser (Speaker), Cansativa GmbH, Head of Legal/In-house lawyer

Model projects are a legitimate means of the political and regulatory process to explore new markets, your products and services. What approaches have proven successful in the past and what new approaches can we see among European neighbours? The political will to end the prohibition of cannabis beyond medicine can be seen in many European countries. How will Germany position itself and how can the experiences from Switzerland and the Netherlands help with the legislative process and implementation? The Netherlands has tolerated a grey market for decades, does Germany face a similar danger with the first pillar and how can pillar 2 contain this threat of a strong illegal market? Langugage: German SpeakersMichael "Der Micha" Knodt (Moderator), Freelance journalistFinn Hänsel (Speaker), SanityGroup GmbH, Founder & Managing DirectorMarc Brüngger (Speaker), Pure Production AG, Head of Innovation & RegulationFrederike S. Fäscher (Speaker), Pivot Regulatory, ConsultantDipl.-Ing. Jörg Meyer-Brenken (Speaker), Fluence, Lead Account Manager Cannabis EMEA

Various differing approaches to cannabis reform are now being developed and implemented throughout the world, from Malta’s cannabis clubs, to Switzerland’s pilot framework, and Germany’s exploration of both. In this panel, we’ll dive into each of these emerging strategies, explore how they are influencing one another, and consider the budding global economic, policy and social trends which are shaping the development of the international cannabis industry. Langugage: English SpeakersBen Stevens (Moderator), Business of Cannabis, EditorDr. Bernd Werse (Speaker), Goethe-Universität, Centre for Drug Research, Social scientist (senior staff member)Carmen Doran (Speaker), Helius Therapeutics, Chief Executive OfficerDr. Pavel Kubu MD (Speaker), Chain Pharmaceuticals GmbH, Chief Information OfficerTom Pettit (Speaker), Smells Like Business, Podcaster & European Cannabis SpecialistHanna Hlushchenko (Speaker), Cannexpor Pharma, BD Director

At a time of rising market volatility, consolidation, and innovation, finding future-proof decisions is challenging.This panel aims to address the need for an ever-expanding matrix of data for informed C-Suite leaders. From traditional COGS reduction strategies, to doubling down on people, and harm reduction, we’ll hear from today’s impact icons on pathways towards a more sustainable industry. Language: English SpeakersLeonid Kotlyar (Moderator), DéWarrior Unlimited B.V., Managing DirectorTjalling Erkelens (Speaker), Bedrocan, Founder and Chairman of the BoardWilliam Muecke (Speaker), Artemis Growth Partners, Co-founder and Managing MemberJürgen Bickel (Speaker), Storz & Bickel GmbH, Managing Director & Co-FounderWilliam Purves (Speaker), Brains Bioceutical, Chief Commercial OfficerPatrick Hoffmann (Speaker), Cantourage Group SE, Founder Cantourage & Member of the Supervisory Board

The Dutch cannabis experiment started! After years of preparation, the first growers will start supplying cannabis, hash and edibles to the coffee shops in the cities of Breda and Tilburg in Q4 of this year. The other growers and participating cities will follow next year. What is going well, what still needs attention, and what can other countries learn from this legalisation? Language: English SpeakersThomas Rau (Moderator), CMO Q-Farms, Founder LCC and CannabisinessClaas van Os (Speaker), Q-farms - Blowing Minds, CEO & co-founder/ Licensed grower of cannabis for recreational consumptionKars Van Laarhoven (Speaker), Dutch Leaf, CEOPatrick Stevens (Speaker), Holigram, AccountmanagerCorné Melissen (Speaker), Hollandse Hoogtes, CEO Kenzoll and Chairman

Delving into worldwide investments in both recreational and medical cannabis, this panel discussion will tackle the complexities of investing across varied regions and sectors, gleaning insights from seasoned cannabis investors around the world. The panel will unpack international investment nuances and spotlight European-specific hurdles, offering advice for entrepreneurs in search of funding. Language: English  SpeakersGeorgia Glick (Moderator), Tocar Strategic Advisors/ Hanway, PartnerAlfredo Pascual (Speaker), Seed Innovations (LON:SEED), Director – Investment ResearchYonatan Meyer (Speaker), Shield Investment, PartnerMatt Francini (Speaker), Gron Ventures, PartnerAndrey Makiyevskiy (Speaker), Leafy Tunnel, Principal

Big tobacco cannot ignore the rise and potential of cannabis as a replacement for tobacco, but what is their right to win? What are some challenges that big tobacco companies face when entering or considering the cannabis industry? This panel will delve into the ethical considerations and historical backdrop. Drawing comparisons in trade, production, and taxation across these industries, the conversation will spotlight strategic alliances, product innovation partnerships, and shifts in consumption techniques. This will shed light on the unfolding dynamics between traditional sectors and the emerging cannabis industry. Language: English  SpeakersLily Temperton (Moderator), Tocar Strategic Advisors/ Hanway, PartnerPaul Furfaro (Speaker), Village Farms International, Senior Vice President, StrategyDeepak Anand (Speaker), Vancouver Island UniversityRicardo Gaeda (Speaker), Lawrence Stephens Limited, Director, Head of Regulatory SolutionsNick Kenny (Speaker), KBS, Director

Internationally for many years across different ethnic around the world, Cannabis smokers have been blending Tabacco leaves within their Marijuana smoking habits. Since the development of the Cannabis industry in the US in the late 90's, two main cannabinoids have became popular in this emerging smoking/vaping industry. The active compound called THC (Delta 9-Tetrahydrocannabinol) with intense mental feeling and its counter pair CBD (Cannabidiol) with relaxing body feeling. In 2014, an EU brand called Kanavape introduce in France for the first time in Europe, CBD vape pen e-liquid based, showing no restriction for selling it as alternative to nicotine e-liquid because there was no THC and no law on CBD. Thanks to Kanavape pioneering step and for winning in 2020 its fight at the European Court of Justice in Luxembourg, against the French gouvernment who denied the legality of CBD products in the European free trade market. From the ruling day of the Kanavape's CBD winning case, Tabacco shops in many EU country like France, Belgium, Luxembourg, Austria, ..., are now introducing to their customer an all new range of legal products, from CBD cannabis extract derivates product such as in e-liquid vaping form, herbal smoking bag, and more. That' s why this year 2022 for Dormund Inter Tabac, it became natural to introduce this innovative market to the international tabacco experts to offer them the chance to understand this new opportunity growing in Europe which is developing more and more across the 5 continents. Language: English SpeakerSébastien Ludovic Béguerie (Speaker)...

In order to meet the regulatory requirements (Novel Food application) and to open up the outstanding prospects of the CBD market (food and nutritional supplements) for our members and partners, EIHA is conducting a Novel Food application for CBD isolates and hemp extracts. The subsidiary responsible for this, EIHA projects GmbH, is investing a total of approx. 3.5 million EUR in the necessary toxicology studies on CBD and THC. The complete submission of all study data is expected in mid-2024. Language: German SpeakerDaniel Kruse (Speaker), EIHA, President

CBD - A Question of Demarcation? CBD: Popular Among Consumers, a Regulatory Challenge. After the CBD hype of recent years, companies are facing increasing challenges in the market. The marketability of products is dependent on category-appropriate marketing. The accusation of misuse and the controlled substances status of industrial hemp still play a role. What does the future hold for industrial hemp products post-legalization? What role do pharmaceutical laws, Novel Food, Cosing, and TPD play now, and what changes will occur with the Cannabis Act? Language: English SpeakersLisa Haag (Moderator), MJ Universe GmbH, CEOSven Kalies (Speaker), BvCW e. V., Bord memberLukas Rausse (Speaker), Arvaloo GmbH, Co-Founder & CEOSébastien Ludovic Béguerie (Speaker), Canèbe S.R.O., Alpha-Cat, Kanavape, Golden Buds, Ing. MSc Plant Sciences, CEO, Founder and Creator

From ADAC e.V. to Cannabis Club e.V. - What legal requirements should be created today in Pillar I in order to successfully implement social clubs? What do prospective cannabis club associations need to know and observe? And is an exit or transition to a model project possible later, when Pillar II comes? An analysis of the law on associations, companies and the upcoming law. Let's regulate! Language: German SpeakersLito Michael Schulte (Moderator), Lito Law Academy GmbH, Managing Director & LawyerEmanuel Kotzian (Speaker), Chillisimo e.V., ChairmanNikita Cretu (Speaker), Lumino, Co-founder & COOLuc Richner (Speaker), Cannavigia - Vigia AG, Co-founder & CEO

A comprehensive understanding of the current position, and where we go from here. The regulation of cannabis for adult use in Europe presents a myriad of challenges for member states. While some are adopting an incremental approach to address the issue, the need for a cohesive and comprehensive regulatory framework at the European level becomes increasingly apparent. Harmonising cannabis regulations across Europe would facilitate consistency, improve public health and safety standards, promote fair market competition, and ultimately pave the way for a more effective and sustainable cannabis industry. Join us as we explore the crucial role of European-level regulation in shaping the future of cannabis policy and its impact on society. Language: English SpeakersNiall Neligan (Moderator), The Cannabis Summit, Barrister-at-Law | CEOKai-Friedrich Niermann (Speaker), KFN+ Law Office, Lawyer and FounderFrantisek Svejda (Speaker), HEMP FACTORY s.r.o., CEOJiří Velechovský (Speaker), SensiQure s.r.o., Co-Founder & Head of CultivationSean Carney (Speaker), Herbology Ventures s.r.o., Executive Director

In the landscape of CBD, a significant hurdle emerges - only a mere 6% of a dose is accessible for the body's absorption, as indicated by a report from the World Health Organization (WHO). This fact beckons a compelling question: How can we unlock enhanced CBD absorption and unleash its full potential? Dr. Sung-Min Pyo, expert in pharmaceutical formulation and frequent guest lecturer at globally renown universities, will lead an illuminating session that peers into the depths of this challenge. Discover the transformative power of advanced drug delivery technologies capable of elevating the body's uptake of CBD and other cannabinoids like THC by an astounding 8-fold. Language: English SpeakerDr. Sung-Min Pyo (Speaker), Pyo Labs Ltd., CEO

The cannabis plant uses a wide palette of terpenes and minor cannabinoids to produce its array of effects. But for consumers and producers of whole plant products, they are plagued by the inconsistencies inherent to a botanical product. The winning cannabinoid products of the future will contain unique formulations of terpenes and cannabinoids for directed consistent effects. Lex Pelger will highlight what's known about some of the most important minor cannabinoids and terpenes and the potential combinations that may become popular. Language: English SpeakerLex Pelger (Speaker), White Whale Creations, Founder

There are over 200 medical cannabis products available in Germany, yet only 2 of them have market authorisation, why is that? Today's panel will be discussing why such few companies have pursued drug development and market authorisation. What role will approved finished drugs play in the future and what is the impact of legalisation of recreational cannabis? Will legislation affect the type of products available to patients? Our expert panel will provide their insights on the future of the German medical market. Language: English SpeakersBijan Christoph Hezarkhani (Moderator), BijanChristoph.com, Business DevelopmentAna Serrato (Speaker), Avextra Pharma, Head Drug DevelopmentBertan Türemis (Speaker), Fette Pharma GmbH, Medical Science LiaisonMaximilian Schmitt (Speaker), Cannaflos - Gesellschaft für medizinisches Cannabis GmbH, Co-Founder & CEO

Building medical cannabis companies and brands that resonate with patients can be extremely difficult in highly regulated markets. Acquiring new patients can be even more challenging, given the stringent restrictions on advertising and marketing. This situation presents a unique set of challenges for medical cannabis companies across Europe. In this masterclass, participants will hear from some of the most successful European medical cannabis companies about how they have managed to connect with patients and acquire them. Attendees will gain actionable advice and insights. Language: English SpeakersGeorgia Glick (Moderator), Tocar Strategic Advisors/ Hanway, PartnerDr. Julian Wichmann (Speaker), Bloomwell Group, Co-FounderDave Barton (Speaker), thermidor, Co-Founder, Creative DirectorCalvin Rasode (Speaker), Brains Bioceutical Corp, Vice President, Marketing

Language: English SpeakerDr. Pavel Kubu MD (Speaker), Chain Pharmaceuticals GmbH, Chief Information Officer

On the basis of results from qualitative interviews and an online survey online survey, the prejudices and practical problems faced by people practical problems people who use cannabis for medical reasons still face people who use cannabis for medical reasons still have to deal with, even in times of (theoretically) legal supply. There is a considerable number of people who, despite manifest symptoms that can be treated with cannabis symptoms that can be treated well with cannabis, or who, after or who, after many years of bad experiences with medicine and law enforcement do not even try to get a legal supply. The inadequate implementation of the Cannabis as Medicine Act not only ensures that such not only ensures that such people continue to be at risk of prosecution, but also that prosecution, but also ensures that there is still a great deal of reluctance in the medical world. Language: German SpeakerDr. Bernd Werse (Speaker), Goethe-Universität, Centre for Drug Research, Social scientist (senior staff member)

Join us as we introduce a diverse panel, bringing together different perspectives of the industry, to provide their insights on what the removal of cannabis from the German Narcotics List really means. What changes are to be expected by patients, pharmacists, physicians and the industry as a whole? Does the reclassification provide opportunities for the industry or is it just another reason for hype? We will take a closer look at this decision by the German government and discuss its implications. Language: German SpeakersBijan Christoph Hezarkhani (Moderator), BijanChristoph.com, Business DevelopmentDr. Armin Prasch, (Speaker), Trias Pharma GmbH, CEOThorsten Hetfeld (Speaker), CannaTHoC Cannabis-Association, FounderMelanie Dolfen, (Speaker), Bezirksapotheken Berlin, Pharmacist & Owner & EntrepreneurGarvin Hirt (Speaker), Copeia, Founding Partner

Multiple informed choices in facility design have to be made by growers/investors. First of all the growing facility going for a indoor facility or a greenhouse facility. But secondly climate, light, substrate all are connected and as a consequence having impact on energy efficiency. All will be discussed in this panel with experts to achieve successful discussions on facility set-up. Language: English SpeakersSonny Moerenhout, (Moderator), Cultivators, Managing PartnerMartin Anker (Speaker), SANlight GmbH, MSc.; CEOMarc Montandon (Speaker), CarbonActive GmbH, OwnerJörg Löser (Speaker), Cannafarm Arnstadt GmbH, CEOBen Nikaj (Speaker), Grodan, Senior Crop Advisor

IPM does not offer a universal remedy; rather, it involves the integration of customized strategies suited to individual circumstances. Through the implementation of these strategies, cultivators equip themselves with a robust methodology to effectively manage pests, pathogens, viruses and viroids. Don't miss this opportunity to gain valuable insights into the realm of medical cannabis cultivation, as our panel of experts share their experiences in navigating the complexities of Integrated Pest Management (IPM) and the new threat of Hop Latent Viroid (HLVD). Language: English SpeakersJan Wegner (Moderator), Four 20 Pharma GmbH, Head of CultivationXavier Gaya (Speaker), Klonetics EU, Cultivation Advisor, Head of SalesFranz Josef Sima (Speaker), Fluence, Horticulture Service Specialist CannabisBen Niehaus (Speaker), SpexAI GmbH, Founder and CTO

Since 2021, Max has been responsible for the lighting design and simulation of all major projects as Sales Application Engineer at SANlight GmbH. Here he can draw on his experience in climate and irrigation planning and provides customers with a holistic view of the project. Taking into account all influencing factors and components in a project of this magnitude is the key to success. Optimising energy consumption, Lich?ntensität during different growth phases and light distribution over the entire cultivation area are just a small part of the topics he can provide insight into. In the meantime, SANlight installations designed by Max can be found all over the world. Language: English SpeakerMax von Knoop (Speaker), SANlight GmbH, M.A.; Field Application Engineer

This masterclass delves into the crucial role of genetics in cannabis production. Genetics dictate the quality, consistency, and cost of products—key factors for consumers. The panellists will discuss the surge in home cultivation in Europe, the seed versus tissue culture debate, and the complexities of aligning consumer tastes with genetic stability. Additionally, the session explores the rise of first-time home growers, the creation of genetic banks, and the history of seed bank collecting. Legacy strains, their fit with current potency demands, and the intricacies of importing from North America are also examined. Addressing issues such as theft, licensing, and import/export limitations, this session offers a succinct insight into cannabis genetics for those eager to understand this evolving sector. Language: English SpeakersLily Temperton (Moderator), Tocar Strategic Advisors/ Hanway, PartnerRavi Dronkers (Speaker), Sensi Seeds, Head of Research and DevelopmentDr. Gavin George (Speaker), Puregene AG, CEOAnthony Shevlin (Speaker), DéWarrior Unlimited B.V., head of agronomyTim Oates (Speaker), Delta Tetra, TreeHouse, CEO, CCO

As of April 1, 2024, Germany has decriminalized cannabis: possession, consumption, and personal cultivation are now penalty-free. Starting July 1, 2024, cultivation associations (colloquially known as "CSCs, Cannabis Social Clubs") are allowed to cultivate cannabis for up to 500 members and distribute it to their members non-profitably. Additionally, medical cannabis is no longer subject to the Narcotics Act and can now be prescribed by any doctor without the need for Btmg paperwork. What do these changes mean for Germany? Where are revisions urgently needed? And what are the chances for Phase 2, where model projects similar to Swiss pilot projects are planned? ModeratorMoritz FörsterSpeakersDirk HeitepriemFinn HänselOlivia EwenikeDr. Philipp GoebelTimo Bongartz

As of July 1, 2024, cultivation associations are allowed to grow cannabis for their up to 500 members and sell it to them without profit. As the "closing panels" of the preceding Intensive Seminar for Cultivation Associations (Cannabis Competence Days, CKT, Wednesday, June 12 – Thursday, June 13), experts from the fields of law, marketing, competition, and cultivation technology delve into the challenges posed by this law. What does it take to establish a cultivation association, grow high-quality cannabis, and distribute it successfully? ModeratorDirk RehahnSpeakersMarcus GeschwandterChristian SchmittMarc MontandonMartin AnkerJörg Löser

In addition to the recent partial legalization of cannabis in Germany, there is a lot happening around the globe: From Dutch and Swiss pilot projects to the advancements and plans in the Czech Republic, Poland, and other European countries, to Thailand, where politics may be vacillating, yet the cannabis economy is simultaneously flourishing and growing. Which country will legalize next? What are the latest future trends? ModeratorGeorgia GlickSpeakersAlfredo PascualAdele HollmannGavin GeorgeNikita CretuElias Galantay

With the new CanG, Germany has removed medical cannabis from the narcotics list. Doctors can now prescribe cannabis to patients without extensive bureaucratic hurdles, and at the same time, the cultivation of medical cannabis in Germany is permitted. What impact does this have on the market regarding prescription numbers for private and insured patients? How do patients benefit from this? What do doctors and pharmacies say about the new legislation? ModeratorGarvin HirtSpeakersLeif BurmeisterChristiane NeubaurMarcus ReussmannNicole Perenyi

The new CanG law has opened the floodgates for proactive marketing towards new cannabis patients. Prescriptions are now available starting from 1€, necessary consultations and the shipping of medical cannabis take place entirely online, and rappers are promoting the whole thing. Is this in the interests of healthcare and patients? What do healthcare professionals and pharmaceutical companies say about this? And what is the position of the companies involved? ModeratorBertan TüremisSpeakersMarla LutherNiels LutzhoeftGero KohlhaasMatthias FischerJanosch W. Kratz